Racemic ketamine is the full ketamine molecule containing both the R-enantiomer (arketamine) and S-enantiomer (esketamine) in equal proportion. It is the form of ketamine used in IV ketamine therapy.
Racemic IV ketamine is delivered intravenously rather than as a nasal spray, allowing precise dose control and consistent absorption. It is used off-label for treatment-resistant depression, PTSD, anxiety, OCD, and chronic pain. The R-enantiomer in racemic ketamine may contribute additional therapeutic effects not present in esketamine alone, though clinical research continues to characterize these differences.
NeuroGlow’s IV ketamine therapy program uses racemic ketamine and is self-pay for psychiatric indications.
Racemic ketamine is what most patients receive when they pursue IV ketamine therapy for depression. The molecule was originally developed in the 1960s as a dissociative anesthetic and has been used in operating rooms for over five decades. Its antidepressant properties at sub-anesthetic doses were first published by Berman et al. in 2000 and later validated by the NIMH (Zarate 2006). At NeuroGlow, racemic ketamine is administered via IV infusion across a 6-session induction series at $3,500 self-pay.